| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Max Schmauss, Emilio Sacchetti, Jean-Pierre Kahn, Rossella Medor. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. International clinical psychopharmacology. vol 22. issue 2. 2007-04-19. PMID:17293708. |
this subgroup analysis of symptomatically stable patients with schizophrenia or other psychotic disorders in the stormi trial determined the efficacy and tolerability of risperidone long-acting injectable in patients changed from oral risperidone monotherapy. |
2007-04-19 |
2023-08-12 |
Not clear |
| Zhu Li, Mei Huang, Adam J Prus, Jin Dai, Herbert Y Meltze. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain research. vol 1134. issue 1. 2007-04-05. PMID:17207474. |
clozapine, risperidone, olanzapine and ziprasidone, to improve cognitive function in schizophrenia. |
2007-04-05 |
2023-08-12 |
rat |
| Hsien-Yuan Lane, Yi-Ching Liu, Chieh-Liang Huang, Yue-Cune Chang, Po-Lun Wu, Chung-Ta Lu, Wen-Ho Chan. Risperidone-related weight gain: genetic and nongenetic predictors. Journal of clinical psychopharmacology. vol 26. issue 2. 2007-04-04. PMID:16633140. |
this study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent. |
2007-04-04 |
2023-08-12 |
Not clear |
| Xiang Yang Zhang, Dong Feng Zhou, Lian Yuan Cao, Gui Ying Wu, Yu Cun She. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study. Journal of clinical psychopharmacology. vol 26. issue 1. 2007-04-03. PMID:16415724. |
the interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study. |
2007-04-03 |
2023-08-12 |
Not clear |
| Elizabeth B Stuyt, Terrie A Sajbel, Michael H Alle. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. The American journal on addictions. vol 15. issue 2. 2007-04-03. PMID:16595355. |
all patients with co-occurring substance dependence and schizophrenia or schizoaffective disorder treated with olanzapine, risperidone, ziprasidone, and typical depot neuroleptics from january 2001 to december 2003 (n = 55) are the subjects of this study. |
2007-04-03 |
2023-08-12 |
human |
| Trino Baptista, Maritza Martinez, Anny Lacruz, Antonio Arellano, Soaira Mendoza, Serge Beaulieu, Luis Hernández, Quilianio Contreras, Tatiana Galeazzi, Doritza Varga. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Schizophrenia research. vol 89. issue 1-3. 2007-04-03. PMID:17029751. |
insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. |
2007-04-03 |
2023-08-12 |
human |
| Jose M Canive, Gregory A Miller, Jessica G Irwin, Sandra N Moses, Robert J Thoma, J Christopher Edgar, Andrea Sherwood, Fernando Torres, Marianna Lanoue, Stephen Lewis, Faith M Hanlon, Michael P Weisend, Valerie Mead, Vicente B Tuaso. Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. Psychopharmacology bulletin. vol 39. issue 1. 2007-04-03. PMID:17065975. |
efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. |
2007-04-03 |
2023-08-12 |
human |
| Georges M Gharabawi, Cynthia A Bossie, Gahan J Pandina, Mary J Kujawa, Andrew J Greenspan, Young Zh. A discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia. The Journal of clinical psychiatry. vol 68. issue 2. 2007-03-09. PMID:17335334. |
a discussion of 2 double-blind studies comparing risperidone and quetiapine in patients with schizophrenia. |
2007-03-09 |
2023-08-12 |
Not clear |
| Mari Murashita, Takeshi Inoue, Ichiro Kusumi, Shin Nakagawa, Kouichi Itoh, Teruaki Tanaka, Takeshi Izumi, Hiroshi Hosoda, Kenji Kangawa, Tsukasa Koyam. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and clinical neurosciences. vol 61. issue 1. 2007-03-07. PMID:17239039. |
glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. |
2007-03-07 |
2023-08-12 |
human |
| Mari Murashita, Takeshi Inoue, Ichiro Kusumi, Shin Nakagawa, Kouichi Itoh, Teruaki Tanaka, Takeshi Izumi, Hiroshi Hosoda, Kenji Kangawa, Tsukasa Koyam. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and clinical neurosciences. vol 61. issue 1. 2007-03-07. PMID:17239039. |
risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia. |
2007-03-07 |
2023-08-12 |
human |
| Mari Murashita, Takeshi Inoue, Ichiro Kusumi, Shin Nakagawa, Kouichi Itoh, Teruaki Tanaka, Takeshi Izumi, Hiroshi Hosoda, Kenji Kangawa, Tsukasa Koyam. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and clinical neurosciences. vol 61. issue 1. 2007-03-07. PMID:17239039. |
the aim of the present study was to investigate glucose and lipid metabolism, and feeding-control parameters in schizophrenia patients treated with long-term risperidone monotherapy. |
2007-03-07 |
2023-08-12 |
human |
| Mari Murashita, Takeshi Inoue, Ichiro Kusumi, Shin Nakagawa, Kouichi Itoh, Teruaki Tanaka, Takeshi Izumi, Hiroshi Hosoda, Kenji Kangawa, Tsukasa Koyam. Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. Psychiatry and clinical neurosciences. vol 61. issue 1. 2007-03-07. PMID:17239039. |
fifteen patients with paranoid-type schizophrenia who had been treated with risperidone and had global assessment of function (gaf) scores >70 were selected and compared with healthy volunteers (n = 25). |
2007-03-07 |
2023-08-12 |
human |
| Takashi Takeuchi, Ko Furuta, Toshiyuki Hirasawa, Hidekazu Masaki, Tomoaki Yukizane, Hidenori Atsuta, Toru Nishikaw. Perospirone in the treatment of patients with delirium. Psychiatry and clinical neurosciences. vol 61. issue 1. 2007-03-07. PMID:17239041. |
other atypical antipsychotics including risperidone, quetiapine and olanzapine have been widely used for treatment, not only for schizophrenia symptoms but also for delirium, because of their low potential to induce extrapyramidal disturbances. |
2007-03-07 |
2023-08-12 |
Not clear |
| Jean-Pierre Lindenmayer, Akbar Khan, Mariëlle Eerdekens, Ilse Van Hove, Stuart Kushne. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 2. 2007-03-02. PMID:17049818. |
long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. |
2007-03-02 |
2023-08-12 |
human |
| Jean-Pierre Lindenmayer, Akbar Khan, Mariëlle Eerdekens, Ilse Van Hove, Stuart Kushne. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 2. 2007-03-02. PMID:17049818. |
subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (study a and study b) after participating in 12-week studies of long-acting injectable risperidone [kane, j.m., eerdekens, m., lindenmayer, j.-p., keith, s.j., lesem, m., karcher, k., 2003. |
2007-03-02 |
2023-08-12 |
human |
| Jean-Pierre Lindenmayer, Akbar Khan, Mariëlle Eerdekens, Ilse Van Hove, Stuart Kushne. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 2. 2007-03-02. PMID:17049818. |
safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. |
2007-03-02 |
2023-08-12 |
human |
| Jean-Pierre Lindenmayer, Akbar Khan, Mariëlle Eerdekens, Ilse Van Hove, Stuart Kushne. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 17. issue 2. 2007-03-02. PMID:17049818. |
it is concluded that treatment with long-acting injectable risperidone for 1 year or longer appeared to be safe and well tolerated in patients with schizophrenia or schizoaffective disorder. |
2007-03-02 |
2023-08-12 |
human |
| Wei Yu, Xinhua S Ren, Austin F Lee, Lawrence Herz, Yu-Hui Huang, Lewis E Kazi. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. PharmacoEconomics. vol 24. issue 12. 2007-02-26. PMID:17129077. |
association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. |
2007-02-26 |
2023-08-12 |
Not clear |
| Wei Yu, Xinhua S Ren, Austin F Lee, Lawrence Herz, Yu-Hui Huang, Lewis E Kazi. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia. PharmacoEconomics. vol 24. issue 12. 2007-02-26. PMID:17129077. |
olanzapine and risperidone are two commonly prescribed atypical antipsychotics for schizophrenia. |
2007-02-26 |
2023-08-12 |
Not clear |
| Hitoshi Takahashi, Mitsuhiro Kamata, Keizo Yoshida, Jun Ishigooka, Hisashi Higuch. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. The Journal of clinical psychiatry. vol 67. issue 10. 2007-02-23. PMID:17107250. |
switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial. |
2007-02-23 |
2023-08-12 |
Not clear |